Expertise in

conditions

Eric Hachulla

CHU Caen

Caen, FR

Expertise in

conditions

CHU Caen

Caen, FR

Overview

Eric Hachulla practices practicing medicine in Caen, France.

Mr. Hachulla is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Sjogren Syndrome, Tissue Biopsy, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 496 peer reviewed articles and participating in 17 clinical trials.

Gender

Male

Locations

CHU Caen
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

Enrollment Status: Completed

Publish Date: May 22, 2026

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)

Enrollment Status: Completed

Publish Date: March 20, 2026

Intervention Type: Other, Biological

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Enrollment Status: Terminated

Publish Date: March 20, 2026

Intervention Type: Drug

Study Drug: HZN-825

Study Phase: Phase 2

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)

Enrollment Status: Completed

Publish Date: February 18, 2025

Intervention Type: Drug

Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper

Study Phase: Phase 3

Enrollment Status: Completed

Publish Date: May 23, 2024

Intervention Type: Behavioral

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

Enrollment Status: Terminated

Publish Date: May 16, 2023

Intervention Type: Drug

Study Drug: Baricitinib

Study Phase: Phase 3

Clinical Characteristic and Quality of Life Assessment in Adulthood of Patients With Cryopyrin Associated Periodic Syndrome

Enrollment Status: Completed

Publish Date: January 18, 2023

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus

Enrollment Status: Completed

Publish Date: November 23, 2022

Intervention Type: Drug

Study Drug: Baricitinib

Study Phase: Phase 3

Determinants of Patients' Uptake of Therapeutic Education Programme

Enrollment Status: Completed

Publish Date: October 17, 2022

Intervention Type: Other

Study Phase: Not Applicable

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310

Enrollment Status: Completed

Publish Date: June 02, 2022

Intervention Type: Drug

Study Drug: UT-15C

Study Phase: Phase 3

View 9 Less Clinical Trials

496 Total Publications

Efficacy and Safety of Riociguat in Early Pulmonary Vascular Disease: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial.

Journal: Chest

Published: March 30, 2026

View All 496 Publications

Frequently Asked Questions about Eric Hachulla

Is Eric Hachulla a top-rated expert for Systemic Sclerosis (SSc)?

MediFind is an objective health platform that identifies experts based on real-world data. Eric Hachulla is classified as an Elite expert for Systemic Sclerosis (SSc), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eric Hachulla participate in research or clinical trials?

Yes. Eric Hachulla has published 496 articles and abstracts on conditions like Systemic Sclerosis (SSc). You can view a list of Eric Hachulla's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hachulla's expertise for a condition

ConditionClose